Related Experiment Videos
Terfenadine does not inhibit non-immunologic contact urticaria
Contact Dermatitis
|April 1, 1987
Summary
This study found that terfenadine, an H1-antagonist, did not significantly reduce skin reactions from common non-immunologic contact urticaria substances. Histamine release is unlikely to be the primary cause of these reactions.
Area of Science:
- Dermatology
- Pharmacology
- Immunology
Background:
- Non-immunologic contact urticaria (NICU) involves skin reactions not mediated by IgE antibodies.
- Understanding NICU mechanisms is crucial for effective treatment strategies.
Purpose of the Study:
- To investigate the underlying mechanisms of NICU.
- To evaluate the efficacy of terfenadine (an H1-antagonist) in mitigating NICU reactions.
Main Methods:
- Twenty subjects were tested with six known NICU-inducing substances: methyl nicotinate, diethyl fumarate, benzoic acid, cinnamic acid, cinnamic aldehyde, and dimethyl sulfoxide.
- Skin reactions (erythema and edema) were assessed visually.
- Skin blood flow changes were monitored using laser-Doppler flowmetry.
Main Results:
- Terfenadine showed no significant inhibitory effect on the erythema or edema caused by the six tested NICU substances.
- Terfenadine effectively inhibited erythema and edema in prick tests using histamine, confirming its H1-antagonist activity.
Conclusions:
- The findings suggest that non-specific histamine release from mast cells is not the primary mechanism driving NICU reactions to the substances tested.
- Further research is needed to elucidate the specific pathways involved in NICU.